From the COVID-19 pandemic, we are now at an exciting emergence of digital healthcare as a leader in transforming healthcare for the future. From scaling remote health, unlocking value-based care, to big data and health security to delivering population health to drive value-based preventative care, digital health is now a transformative resource and there is no looking back. There are significant challenges and capabilities that need to be brought up to speed across the care continuum. In this virtual roundtable we will explore the top trends in digital health catalyzed by the pandemic, evolution of the digital health investment landscape, and the current opportunities and challenges facing current digital corporations such as total virtualization, scaling up, value-based care, fragmentation, hybrid care, health security and disparities in population-based care.
Thursday December 2nd
Boston 12:00 pm - 1:00 pm EST
San Diego 9:00 am - 10:00 am PST
HBSHAA Members - Free
HBS Alumni - Free
All other attendees - $30
(As a special welcome to reengage in the San Diego area, all HBS Alumni may register for free. Please login to see your available ticket options.)
Midori Uehara, MBA 2017, VP- Business Development, Cedar,
Pia Gugnani Bhatia, MBA 2017, Director, Strategy& (part of the PwC network
Our Moderator, Dr. Anita Gupta, GMP 29
Midori Uehara is the VP of business development at Cedar, the market-leading patient financial engagement platform. She was part of the founding team of OODA Health, acquired by Cedar in June 2021, where she led provider partnerships and GTM strategy (along with wearing many other hats). Midori has worked broadly across the healthcare ecosystem, with previous experience at Castlight Health, in state-level health policy, and at primary and specialty care providers. She started her career in management consulting at Bain & Company. Midori holds an MBA and MPP from Harvard University and graduated Phi Beta Kappa with a BA in Human Biology from Stanford University.
Pia Gugnani Bhatia is a Director at Strategy&, PwC where she is a leader within the firm's digital health practice. Pia works across the healthcare ecosystem - with biopharma, health systems, and startups - advising on growth plays, go-to-market strategies, and cross-sector partnerships. Previously, Pia has also worked at Boston Children's Hospital to optimize patient and family experience and at Quartet, a leading behavioral health platform. Pia has an MBA from Harvard Business School and BA in Economics and International Studies from Yale University.
Dr. Anita Gupta is Chief Executive Officer of the Strata Group, Inc., a leading global healthcare business firm specializing in strategy, policy, and innovation. She serves as a Board of Director of HealthyWomen and Board Advisor of Bionaut, Inc. Dr. Gupta served on the Board of Directors of Amorsa Therapeutics, Inc, a biopharmaceutical neuroscience company, aligning a strategic collaboration facilitated by Johnson & Johnson. Dr. Gupta has held the positions of Senior Vice President, Medical Strategy and Government Affairs at Heron Therapeutics, Inc, a publicly traded biopharmaceutical company focused on oncology and pain therapeutics, and Vice-Chair of Tenet Healthcare at Drexel University School of Medicine. She serves as an FDA advisor, Department of Defense advisor, and appointed member of the National Academies of Sciences, Engineering and Medicine Global Forum and a Distinguished Fellow of the National Academies of Practice. Dr. Gupta serves as appointed faculty at the Johns Hopkins School of Medicine, Anesthesiology and Critical Care. Dr. Gupta holds an M.P.P. and H.H.P. from Princeton University, GMP in Business Management from Harvard Business School, B.S and Pharm.D. in Pharmacy, from Rutgers University, and a D.O. from the University of Medicine and Dentistry of New Jersey. Dr. Gupta is board-certified in anesthesiology and pain medicine and is a fellow of the American Society of Anesthesiologists and named a Goldman Sachs 10K Small Business Scholar, Top 100 Inspiring Leader by PharmaVoice, Top 10 Emerging Leader by Pharmaceutical Executives, and Top 10 Women of Influence by Fierce Healthcare.